Acute gastrointestinal bleeding (AGIB) is a common complication in the decompensated stage of liver cirrhosis, of which approximately 70% is acute variceal bleeding (AVB) caused by portal hypertension. Existing evidence suggests that both terlipressin and somatostatin can be used to control AVB in cirrhotic patients, but terlipressin may be the first-line treatment for cirrhotic patients with AGIB complicated by acute kidney injury (AKI). Herein, a multicenter randomized controlled trial (RCT) has been designed to compare the efficacy of terlipressin and somatostatin in the treatment of cirrhotic patients with AGIB complicated by AKI.
patients have a definite diagnosis of live cirrhosis and AKI;
patients present with AGIB at admission;
patients' age 18-70 years old;
patients or relatives can sign the informed consent form.
patients have hepatorenal syndrome- acute renal injury (HRS-AKI);
patients have structural kidney injury;
patients have chronic kidney disease;
patients received terlipressin or somatostatin therapy within 48 hours before enrollment;